QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 icecure-announces-fda-advisory-panel-meeting-date-for-marketing-authorization-of-prosense-in-early-stage-low-risk-breast-cancer-scheduled-for-november-7-2024

Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women...

 uspto-grants-notice-of-allowance-for-additional-patent-on-icecures-novel-cryogenic-pump-technology-reinforcing-cos-global-ip-leadership-in-cryoablation-technologies

Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fieldsOver 50...

 hc-wainwright--co-maintains-buy-on-icecure-medical-lowers-price-target-to-25

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from ...

 icecure-medical-q2-2024-gaap-eps-006-beats-007-estimate-sales-101m-beat-92550k-estimate

Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.0...

 icecure-medical-announces-publication-of-independent-study-titled-acceptance-and-results-of-cryoablation-for-the-treatment-of-early-breast-cancer-in-non-surgical-patients-in-british-journal-of-radiology

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100%Study ...

 icecure-medical-receives-receipt-from-nasdaq-minimum-bid-price-notification

IceCure Medical Ltd. (NASDAQ:ICCM) (the "Company"), developer of minimally-invasive cryoablation technology that destro...

 icecure-medical-announces-independent-study-results-for-prosense-cryoablation-system-published-in-peer-reviewed-journal-cancers

Study Shows High Complete Ablation Rate And Satisfactory Overall Survival In Breast Cancer Patients; Conducted At University Ho...

 hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

 us-fda-grants-regulatory-clearance-to-icecure-for-next-gen-xsense-cryoablation-system-with-cryoprobes

IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minima...

 icecure-medical-reports-data-from-its-kidney-cancer-clinical-study-presented-at-interventional-radiology-conference-dsud-minimally-invasive-approach-results-in-shorter-hospitalization-and-minor-impact-on-renal-function

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors w...

 hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

 hc-wainwright--co-reiterates-buy-on-icecure-medical-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Icecure Medical (NASDAQ:ICCM) with a Buy and maintains $3 price target.

 icecure-medical-q1-eps-008-inline-sales-74300k-miss-87550k-estimate

Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION